Detalhe da pesquisa
1.
ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.
J Pathol
; 261(1): 71-84, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550801
2.
Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer.
Int J Mol Sci
; 23(15)2022 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35897761
3.
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.
Commun Biol
; 7(1): 276, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448753
4.
Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone.
EBioMedicine
; 104: 105163, 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38772281
5.
CDC20 Is Regulated by the Histone Methyltransferase, KMT5A, in Castration-Resistant Prostate Cancer.
Cancers (Basel)
; 15(14)2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509260
6.
The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer.
Sci Rep
; 13(1): 17031, 2023 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37813880
7.
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
Oncogene
; 42(12): 926-937, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725887
8.
ST6GAL1: A key player in cancer.
Oncol Lett
; 18(2): 983-989, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31423157